Syndetics cover image
Image from Syndetics

Amgen : launching Repatha / Tim Calkins, Mike Harris.

By: Contributor(s): Material type: TextSeries: Publisher: London : Kellogg School of Management, 2017Description: 1 online resource : illustrationsContent type:
  • text
Media type:
  • computer
Carrier type:
  • online resource
ISBN:
  • 9781526431127 (ebook) :
Subject(s): DDC classification:
  • 616.12
Online resources: In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven that the molecule is both safe and effective for patients with high cholesterol. It also is effective for patients with familial hypercholesterolemia, a difficult-to-treat population that has exceptionally high levels of cholesterol. Amgen expects the FDA to approve the molecule before the end of the year. Now, the Repatha team has to develop a revenue forecast.
No physical items for this record

Originally published in Calkins, T., & Harris, M. (2017). Amgen: Launching Repatha. 5-416-759. Evanston, IL: Kellogg School of Management at Northwestern University.

In March 2015, Amgen is preparing for the launch of Repatha, a new molecule that has demonstrated a remarkable ability to treat high cholesterol. Through a series of clinical trials, Amgen has proven that the molecule is both safe and effective for patients with high cholesterol. It also is effective for patients with familial hypercholesterolemia, a difficult-to-treat population that has exceptionally high levels of cholesterol. Amgen expects the FDA to approve the molecule before the end of the year. Now, the Repatha team has to develop a revenue forecast.

Description based on XML content.

Licensed e-book